A Phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies

Investigational New Drugs

Volumn 29, Issue 6, 2011, Pages 1426-1431

  Heath, Elisabeth I ^a   LoRusso, Patricia ^a   Ramalingam, Suresh S ^b   Awada, Ahmad ^c   Egorin, Merrill J ^d   Besse Hamer, Tatiana ^d   Cardoso, Fatima ^c   Valdivieso, Manuel ^a   Has, Teresa ^e   Alland, Leila ^e   Zhou, Xiaofei ^e   Belani, Chandra P ^f  

^a WAYNE STATE UNIVERSITY   (United States)

^b EMORY UNIVERSITY   (United States)

^c JULES BORDET INSTITUTE   (Belgium)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

^f PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Oral; Paclitaxel; Phase I

Indexed keywords

3' TERT BUTYL 3' N TERT BUTYLOXYCARBONYL 4 DEACETYL 3' N DEBENZOYL 3' DEPHENYL 4 O METHOXYCARBONYLPACLITAXEL; ANTINEOPLASTIC AGENT; BMS-275183; BRIDGED COMPOUND;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; CONTINUOUS INFUSION; COUGHING; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FACE PAIN; FATIGUE; FEMALE; HEMATEMESIS; HEMATOLOGIC DISEASE; HUMAN; HYPERBILIRUBINEMIA; LEUKOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MUCOSA INFLAMMATION; MUSCLE SPASM; MYALGIA; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PAIN; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; TASTE DISORDER; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; NEOPLASM; ORAL DRUG ADMINISTRATION; PATHOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS; BRIDGED COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; SEPSIS; TREATMENT OUTCOME;

EID: 84856051059     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9498-z     Document Type: Article

References (7)

1. Huizing MT et al (1997) Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. J Clin Oncol 15(1):317-329 (Pubitemid 27020590)
2. Mastalerz H et al (2003) The discovery of BMS-275183: an orally efficacious novel taxane. Bioorg Med Chem 11(20):4315-4323 (Pubitemid 37103102)
3. Rose WC et al (2001) Preclinical pharmacology of BMS-275183, an orally active taxane. Clin Cancer Res 7(7):2016-2021 (Pubitemid 32994840)
4. Clay R, BMS-275183: One-Month Oral Toxicity Study in Rats. (Study No. 99727). Covance Report, 2000. 1.0
5. Gill M, BMS-275183: One-Month Oral Toxicity Study in Dogs. (Study No. 99728). Covance Report, 2000. 1.0
6. Broker LE et al (2006) Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity. Clin Cancer Res 12(6):1760-1767
7. Broker LE et al (2007) A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183. Clin Cancer Res 13(13):3906-3912 (Pubitemid 47037598)